BioLineRx Ltd (BLRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioLineRx Ltd (BLRX) has a cash flow conversion efficiency ratio of -0.138x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.23 Million) by net assets ($23.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BioLineRx Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
BioLineRx Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how BioLineRx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioLineRx Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioLineRx Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kko International SA
PA:ALKKO
|
-0.098x |
|
Livium Ltd
AU:LIT
|
-0.405x |
|
CLEANTEK Industries Inc
V:CTEK
|
0.193x |
|
Arts-Way Manufacturing Co Inc
NASDAQ:ARTW
|
0.011x |
|
Elysee Development Corp
V:ELC
|
0.139x |
|
Peak Processing Limited
AU:PKP
|
0.576x |
|
Millennium Pharmacon International
JK:SDPC
|
-0.062x |
|
Ralco Corporation Bhd
KLSE:7498
|
0.037x |
Annual Cash Flow Conversion Efficiency for BioLineRx Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of BioLineRx Ltd from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see BLRX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $23.34 Million | $-8.14 Million | -0.349x | +89.30% |
| 2024-12-31 | $13.46 Million | $-43.87 Million | -3.259x | -90.63% |
| 2023-12-31 | $13.22 Million | $-22.61 Million | -1.710x | -231.27% |
| 2022-12-31 | $50.84 Million | $-26.24 Million | -0.516x | -49.07% |
| 2021-12-31 | $68.09 Million | $-23.57 Million | -0.346x | +67.13% |
| 2020-12-31 | $22.03 Million | $-23.21 Million | -1.053x | -55.13% |
| 2019-12-31 | $33.38 Million | $-22.67 Million | -0.679x | -15.98% |
| 2018-12-31 | $41.32 Million | $-24.19 Million | -0.585x | -50.68% |
| 2017-12-31 | $52.88 Million | $-20.55 Million | -0.389x | +6.22% |
| 2016-12-31 | $35.03 Million | $-14.51 Million | -0.414x | -39.23% |
| 2015-12-31 | $47.61 Million | $-14.17 Million | -0.298x | +34.72% |
| 2014-12-31 | $31.77 Million | $-14.48 Million | -0.456x | +73.68% |
| 2013-12-31 | $11.68 Million | $-20.23 Million | -1.732x | -28.90% |
| 2012-12-31 | $14.97 Million | $-20.11 Million | -1.344x | -169.77% |
| 2011-12-31 | $22.53 Million | $-11.22 Million | -0.498x | -261.89% |
| 2010-12-31 | $37.26 Million | $11.46 Million | 0.308x | +144.52% |
| 2009-12-31 | $31.13 Million | $-21.51 Million | -0.691x | +48.70% |
| 2008-12-31 | $20.75 Million | $-27.96 Million | -1.347x | -- |
About BioLineRx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more